Initial introduction and spread of the SARS-CoV-2 AY.4.2.1 Delta variant in Bulgaria, a genomic insight.
SARS coronavirus
epidemiology
mutation/mutation rate
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
25
07
2022
received:
23
06
2022
accepted:
26
07
2022
pubmed:
29
7
2022
medline:
18
10
2022
entrez:
28
7
2022
Statut:
ppublish
Résumé
The evolution of the emerging SARS-CoV-2 variants carrying mutations in the spike protein raises concerns about the possibility of accelerated transmission in the ever-evolving COVID-19 pandemic worldwide. AY.4.2, a sublineage of the Delta variant, was considered a variant under investigation (VUI) and also gained the nickname "Delta Plus," due to its extra mutations, Y145H and A222V. In this study, using genomic epidemiology, we provide the first insights into the introduction of AY.4.2 in Bulgaria and the AY.4.2.1 sublineage that found larger dissemination only in Bulgaria and the United Kingdom.
Identifiants
pubmed: 35902787
doi: 10.1002/jmv.28033
pmc: PMC9353378
doi:
Substances chimiques
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6060-6064Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Zoumpourlis V, Goulielmaki M, Rizos E, Baliou S, Spandidos DA. [Comment] The COVID−19 pandemic as a scientific and social challenge in the 21st century. Mol Med Rep. 2020;22(4):3035-3048.
Kupferschmidt K. New coronavirus variants could cause more reinfections, require updated vaccines. Science. 2021. https://www.science.org/content/article/new-coronavirus-variants-could-cause-more-reinfections-require-updated-vaccines
Alexiev I, Ivanov I, Philipova I, et al. Postvaccination SARS-CoV-2 Alpha (B. 1.1. 7) lineage infection among healthcare workers on the background of IgG antibodies. J Med Virol. 2021;94:836-839. doi:10.1002/jmv.27394
World Health Organization. Tracking SARS-CoV-2 Variants. 2022. Accessed June 9, 2022. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
Arora P, Sidarovich A, Krüger N, et al. B. 1.617. 2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination. Cell Rep. 2021;37(2):109825.
O'Toole A, Scher E, Underwood A, et al. Lineages list. Virus Evolution. 2021. Accessed June 9, 2022. doi:10.1093/ve/veab064
SARS-CoV-2 variants of concern and variants under investigation in England: technical briefing 29 (PDF). GOV.UK. Retrieved November 26, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1036501/Technical_Briefing_29_published_26_November_2021.pdf
European Centre for Disease Prevention and Control. SARS-CoV-2 Variants of Concern as of 25 May. 2022. Accessed June 9, 2022. https://www.ecdc.europa.eu/en/covid-19/variants-concern
Gohl M, Garbe J, Grady P, et al. A rapid, cost-effective tailed amplicon method for sequencing SARS-CoV-2. BMC Genom. 2020;21(1):1-10.
DNA Pipelines R&D. COVID-19 ARTIC v3 Illumina Library Construction and Sequencing Protocol-Tailed Method. 2022. Accessed June 9, 2022. doi:10.17504/protocols.io.bky5kxy6
Rambaut A, Holmes EC, O'Toole Á, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat. Microbiol. 2020;5(11):1403-1407.
Moshiri N. ViralMSA: massively scalable reference-guided multiple sequence alignment of viral genomes. Bioinformatics. 2021;37(5):714-716. doi:10.1093/bioinformatics/btaa743
Heng LI. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics. 2018;34(18):3094-3100. doi:10.1093/bioinformatics/bty191
Minh BQ, Schmidt HA, Chernomor O, et al. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. Mol Biol Evol. 2020;37(5):1530-1534. doi:10.1093/molbev/msaa015
Sagulenko P, Puller V, Neher RA. TreeTime: maximum-likelihood phylodynamic analysis. Virus Evol. 2018;4(1):042. doi:10.1093/ve/vex042
Aksamentov I, Roemer C, Hodcroft EB, Neher RA. Nextclade: clade assignment, mutation calling and quality control for viral genomes. JOSS. 2021;6(67):3773. doi:10.5281/zenodo.5607694
Lineage comparison. Gangavarapu K, Latif AA, et al. outbreak.info. 2022. Accessed August 7, 2022. https://outbreak.info/compare-lineages?pango=AY.4.2%26gene%3DS%26threshold%3D0.2%29
S:R158G Mutation Report. Latif AA, Mullen JL, et al. outbreak.info. 2022. Accessed November 22, 2021. https://outbreak.info/situation-reports?pango&muts=S%3AR158G
United Kingdom Health Security Agency (UKHSA). SARS-CoV-2 variants of concern and variants under investigation in England. Technical Briefing 26; 2021. Accessed August 22, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1028113/Technical_Briefing_26.pdf
Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant. N Engl J Med. 2021;385:585-594. doi:10.1056/NEJMoa2108891
Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health Scotland and the EAVE II C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461-2462.
Stowe J, Andrews N, Gower C, et al. Effectiveness of COVID-19 Vaccines Against Hospital Admission with the Delta (B. 1.617. 2) Variant. Public Health England; 2021. Accessed August 22, 2021. https://media.tghn.org/articles/Effectiveness_of_COVID-19_vaccines_against_hospital_admission_with_the_Delta_B._G6gnnqJ.pdf
Arora P, Kempf A, Nehlmeier I, et al. No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2. Cell Mol Immunol. 2022;19:449-452. doi:10.1038/s41423-021-00811-8
Lassaunière R, Polacek C, Fonager J, et al. Neutralisation of the SARS-CoV-2 Delta variant sub-lineages AY. 4.2 and B. 1.617. 2 with the mutation E484K by Comirnaty (BNT162b2 mRNA) vaccine-elicited sera, Denmark, 1 to 26 November 2021. Eurosurveillance. 2021;26(49):2101059.